Chardonnet Laurent
Known title: Chief Financial OfficerCIK: 0001329010
Chardonnet Laurent's purchase track record
How the stock did after each of Chardonnet Laurent's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since June 1, 2022
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+9.4%
3 months: +18.4%
Beat the S&P 500
67%
median +1.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/23/2023 | PRLD | $28K | -39.5% | -40.7% | +9.5% |
| 12/8/2022 | PRLD | $48K | +18.4% | +9.4% | +8.3% |
| 6/1/2022 | PRLD | $42K | +71.0% | +58.4% | -0.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PRLD | ▲ Buy | Open Market | 5,000 | $28K | 5/23/2023 | View on chart |
| PRLD | ▲ Buy | Open Market | 10,000 | $48K | 12/8/2022 | View on chart |
| PRLD | ▲ Buy | Open Market | 10,000 | $42K | 6/1/2022 | View on chart |
| PRLD | ▲ Buy | Grant | 6,500 | $49K | 3/21/2022 | View on chart |
| PRLD | ▲ Buy | Grant | 5,000 | $61K | 12/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
PRLD announces collaboration and supply deal with Eli Lilly
Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.
PRLD announces collaboration and supply deal with Eli Lilly. Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.